Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases

Eur Respir J. 2020 Jul 9;56(1):2001398. doi: 10.1183/13993003.01398-2020. Print 2020 Jul.

Abstract

Diagnostic, treatment and outcome details of 49 COVID-19 patients with concurrent or previous tuberculosis from 8 countries show varied clinical profiles https://bit.ly/369ZGGu

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antitubercular Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • Azithromycin / therapeutic use
  • Betacoronavirus
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques
  • Cohort Studies
  • Coinfection
  • Coronavirus Infections / complications*
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / drug therapy
  • Drug Combinations
  • Emigrants and Immigrants
  • Female
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Lopinavir / therapeutic use
  • Lung / diagnostic imaging
  • Male
  • Middle Aged
  • Mortality
  • Pandemics
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / drug therapy
  • Ritonavir / therapeutic use
  • SARS-CoV-2
  • Tomography, X-Ray Computed
  • Tuberculosis / complications
  • Tuberculosis / diagnosis
  • Tuberculosis / drug therapy
  • Tuberculosis, Pulmonary / complications*
  • Tuberculosis, Pulmonary / diagnosis
  • Tuberculosis, Pulmonary / drug therapy

Substances

  • Antitubercular Agents
  • Antiviral Agents
  • Drug Combinations
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Hydroxychloroquine
  • Azithromycin
  • Ritonavir

Supplementary concepts

  • COVID-19 drug treatment